• Review highlights expanding landscape of CRC biomarkers beyond RAS and BRAF

    Clinically validated biomarkers including MSI, RAS and BRAF mutations, HER2 amplification, and CEA guide targeted therapy, while circulating tumor DNA and multi-omics profiling remain investigational with limited standardization. (Cells)